The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
LLM 2021 | Future advancements in the treatment of myeloma
James Berenson, MD, Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, shares his perspectives on future developments in managing multiple myeloma. The approval of multiple novel treatments have increased the number of treatment options for patients, and further research will be required to improve efficacy and reduce toxicity. Patient response to treatment will additionally be more accurately assessed with the development of new markers to detect solubilized B cell maturation antigen (BCMA). This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
Disclosures
Speaker’s Bureau, Consulting, and Research Grant Support: BMS, Takeda Oncology, Karyopharm, Oncopeptides, and AMGEN
Speaker’s Bureau: Janssen and AMAG
Major Stockholder: ONCOtracker
